Though some cancer patients lack sufficient enzymes to metabolize capecitabine or 5-FU, many patients are not warned about the risks associated with these treatments.

The Trump administration is changing the emergency abortion guidance currently in place at the nation's hospitals.

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

Adding rusfertide to standard care can reduce the need for phlebotomy and improve symptoms in patients with polycythemia vera who require frequent phlebotomies, data suggest.

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

(HealthDay News) — Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published in JAMA Oncology.

Mitomycin plus BCG is as safe and effective as BCG alone, but the combination allows for a reduction in BCG doses and may help combat the BCG shortage.

The US Food and Drug Administration (FDA) has expanded the approved use of Nubeqa (darolutamide) for patients with metastatic castration-sensitive prostate cancer (mCSPC). The drug is now approved for ...

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

The number of cancer survivors in the United States reached 18.6 million as of January 1 this year and is projected to exceed 22 million by 2035.

Adjuvant cemiplimab improved DFS in patients with CSCC who had completed adjuvant radiotherapy and had a high risk of recurrence.

Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.